(YMAB) Y mAbs Therapeutics - Performance -60.9% in 12m
YMAB performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-84.41%
#150 in Peer-Group
Rel. Strength
7.31%
#7056 in Stock-Universe
Total Return 12m
-60.91%
#147 in Peer-Group
Total Return 5y
-89.52%
#113 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | 119 |
| High / Low | USD |
|---|---|
| 52 Week High | 15.69 USD |
| 52 Week Low | 3.64 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 64.03 |
| Buy/Sell Signal +-5 | 0.60 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: YMAB (-60.9%) vs XBI (-10.8%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
9.2% | 80.8% | 81.6% | 23 | 13.8 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-8.02% | -1.47% | 149% | 12.9 | 12 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
10.1% | 2.09% | 57% | 26.2 | 13.8 | 0.96 | 0.60% | 41% |
| BIM PA Biomerieux |
3.05% | 33.4% | 9.65% | 32.6 | 25.6 | 1.54 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
6.43% | -8.71% | 7.86% | 42.4 | 24.4 | 0.27 | 18.7% | -34.3% |
| PTCT NASDAQ PTC Therapeutics |
10.5% | 38.9% | 4.12% | 7.86 | 6.36 | 0.81 | - | 68% |
| KMDA NASDAQ Kamada |
-0.15% | 37.3% | -12% | 24.6 | 20.4 | 0.81 | 48.1% | 3.93% |
| ERF PA Eurofins Scientific SE |
9.39% | 16% | 11.2% | 28.1 | 14.3 | 0.59 | -62.1% | -19.3% |
Performance Comparison: YMAB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for YMAB
| Total Return (including Dividends) | YMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 13.22% | 7.80% | 1.73% |
| 3 Months | -0.42% | -2.75% | 8.59% |
| 12 Months | -60.91% | -10.76% | 11.46% |
| 5 Years | -89.52% | -18.55% | 109.12% |
| Trend Score (consistency of price movement) | YMAB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 82.4% | 84.2% | 69.9% |
| 3 Months | -12.5% | -2.8% | 69.3% |
| 12 Months | -83.6% | -77.8% | 43.2% |
| 5 Years | -71% | -53.5% | 84.1% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | #76 | 5.03% | 11.29% |
| 3 Month | #92 | 2.39% | -8.30% |
| 12 Month | #145 | -56.20% | -64.93% |
| 5 Years | #117 | -87.13% | -94.99% |
FAQs
Does Y mAbs Therapeutics (YMAB) outperform the market?
No,
over the last 12 months YMAB made -60.91%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.76%.
Over the last 3 months YMAB made -0.42%, while XBI made -2.75%.
Performance Comparison YMAB vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
YMAB vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -10.3% | 11.5% | -49.5% | -72% |
| US NASDAQ 100 | QQQ | -10.1% | 11% | -49.7% | -72% |
| German DAX 40 | DAX | -7.4% | 13.9% | -64.8% | -89% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -10.3% | 14.1% | -49.9% | -73% |
| Hongkong Hang Seng | HSI | -11.7% | 7.5% | -66.4% | -88% |
| India NIFTY 50 | INDA | -9.1% | 13.2% | -48% | -61% |
| Brasil Bovespa | EWZ | -12.2% | 13.9% | -66.7% | -69% |
YMAB vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -9.5% | 10.8% | -52.2% | -85% |
| Consumer Discretionary | XLY | -10.4% | 14.9% | -40.4% | -80% |
| Consumer Staples | XLP | -9.7% | 11.9% | -50% | -69% |
| Energy | XLE | -16.3% | 10.5% | -50.4% | -64% |
| Financial | XLF | -8.1% | 15.4% | -51.7% | -85% |
| Health Care | XLV | -11.9% | 10% | -47.4% | -56% |
| Industrial | XLI | -9.1% | 12.3% | -54.7% | -79% |
| Materials | XLB | -10.2% | 11.7% | -49% | -60% |
| Real Estate | XLRE | -10.7% | 11.3% | -49.5% | -74% |
| Technology | XLK | -11% | 10.4% | -50.4% | -67% |
| Utilities | XLU | -10.9% | 11% | -56.5% | -81% |
| Aerospace & Defense | XAR | -10.4% | 5.1% | -68.1% | -102% |
| Biotech | XBI | -9.9% | 5.4% | -39.6% | -50% |
| Homebuilder | XHB | -9.7% | 20.1% | -32.8% | -51% |
| Retail | XRT | -6.8% | 12.1% | -41.4% | -62% |
YMAB vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -23% | -2.06% | -58.2% | -67% |
| Natural Gas | UNG | -5.9% | 23.3% | -65% | -42% |
| Gold | GLD | -14.3% | 7.6% | -79.5% | -109% |
| Silver | SLV | -11.5% | 3.1% | -68.9% | -86% |
| Copper | CPER | -9.1% | 12% | -64% | -69% |
YMAB vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -11.8% | 12.3% | -47.9% | -57% |
| iShares High Yield Corp. Bond | HYG | -10.7% | 12.9% | -52.9% | -70% |